...
首页> 外文期刊>Neurotoxicology and teratology >Developmental treatment with the dopamine D2/3 agonist quinpirole selectively impairs spatial learning in the Morris water maze.
【24h】

Developmental treatment with the dopamine D2/3 agonist quinpirole selectively impairs spatial learning in the Morris water maze.

机译:用多巴胺D2 / 3激动剂喹吡罗的发育处理选择性地损害了莫里斯水迷宫中的空间学习。

获取原文
获取原文并翻译 | 示例
           

摘要

Developmental exposure to the dopamine D2/3 receptor agonist quinpirole is reported to induce D2 priming, impair Morris water maze performance, reduce acoustic startle prepulse inhibition (PPI), and alter locomotor activity. We treated rats from postnatal days 1-21 with the dose reported to induce these effects, 1.0 mg/kg/day, and two higher doses, 2.0 and 4.0 mg/kg/day, or saline. Offspring were tested in the Morris water maze, PPI, exploratory locomotor activity, activity after quinpirole and (+)-methamphetamine challenge, elevated zero maze, light-dark box, marble burying, straight channel swimming, and Cincinnati water maze. In the Morris water maze, all quinpirole groups had longer latencies on test days 3-5 of acquisition, but no effects on reversal or shifted-reduced platform trials. The quinpirole 4.0 mg/kg group had significantly reduced mean search distances on probe trials when combined across the 3 phases of testing but not separately. The male 4.0 mg/kg quinpirole group showed a greater increase in methamphetamine-stimulated activity during the first 10 min after drug challenge but not in the remainder of the 2 h test. No quinpirole effects were found for light-dark box, marble burying, exploratory locomotor activity, straight channel, Cincinnati water maze, or locomotor activity after quinpirole challenge. No effects were found on most measures in the elevated zero maze however the quinpirole 4.0 mg/kg females had longer latencies to enter an open quadrant. The results partially support prior Morris maze deficits induced by developmental quinpirole treatment but little evidence of dopamine D2/3 priming was found using locomotor activity with quinpirole or methamphetamine challenge or acoustic startle/PPI. The limited comparability to published data using developmental quinpirole exposure may be attributable to differences in experimental procedures or may be the result of quinpirole having limited effects. The data suggest that caution is warranted concerning the developmental efficacy of quinpirole.
机译:据报道,多巴胺D2 / 3受体激动剂喹吡罗的发育暴露可引起D2引发,损害莫里斯水迷宫性能,降低声惊吓前脉冲抑制(PPI)并改变运动能力。我们对出生后1-21天的大鼠进行了处理,据报道其诱导这些作用的剂量为1.0 mg / kg /天,另有两种剂量分别为2.0和4.0 mg / kg /天或盐水。在Morris水迷宫,PPI,探索性运动活动,喹吡罗和(+)-甲基苯丙胺攻击,零迷宫升高,浅色暗盒,大理石掩埋,直通道游泳和辛辛那提水迷宫中测试后代。在莫里斯水迷宫中,所有喹吡罗类药物在采集的第3-5天都有较长的潜伏期,但对逆转或降低位移的平台试验没有影响。喹吡罗4.0 mg / kg组在三个试验阶段(但未单独进行)组合使用时,探针试验的平均搜索距离明显缩短。男性4.0 mg / kg喹吡罗组在用药激发后的前10分钟内显示出由甲基苯丙胺刺激的活性更大的增加,但在2小时试验的其余时间内没有。对于喹啉吡咯酮激发后的暗盒,大理石埋葬,探索性运动活动,直通道,辛辛那提水迷宫或运动活性,未发现喹吡罗作用。在升高的零迷宫中,大多数措施均未发现影响,但是喹吡罗4.0 mg / kg雌性进入潜伏象限的潜伏期较长。结果部分地支持了发育性喹吡罗治疗诱发的先前的莫里斯迷宫缺陷,但使用喹吡罗或甲基苯丙胺攻击或听觉惊吓/ PPI的运动活性,很少发现多巴胺D2 / 3启动的证据。使用发育性喹吡罗暴露与公开数据的可比性有限可能归因于实验程序的差异,或者可能是喹吡罗具有有限作用的结果。数据表明,对喹吡罗的开发功效应谨慎对待。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号